Clinical Research Directory
Browse clinical research sites, groups, and studies.
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Sponsor: Boston Children's Hospital
Summary
The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.
Official title: Implementation of High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Infliximab or Vedolizumab
Key Details
Gender
All
Age Range
5 Years - 25 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2020-11-01
Completion Date
2025-12-31
Last Updated
2025-03-03
Healthy Volunteers
No
Interventions
vitamin D3
Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.
Locations (1)
Boston Children's Hospital
Boston, Massachusetts, United States